Roivant CEO urges patience on future after $7B+ sale to Roche
Now that Roivant has ended months of rumors by signing a deal to sell its anti-TL1A inhibitor to Roche for $7.1 billion upfront, everyone wants to know how the company plans to spend that money.
In an investor call Monday morning, analysts asked several questions about Roivant’s next steps. CEO Matt Gline stressed he and his team will “be patient” when it comes to finding the right opportunity. He didn’t go into specifics about when the money will be spent (or on what) and said it’s too early to decide what to do with the cash.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.